ISSN: 1948-5956
Journal of Cancer Science & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

A Pilot Clinical Trial of Radioprotective Effects of Curcumin Supplementation in Patients with Prostate Cancer

Jalal Hejazi1, Reza Rastmanesh1*, Forough-Azam Taleban1, Seyed-Hadi Molana2, Golamreza Ehtejab2
1Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Radiation Oncology, Beasat Hospital, Armey Medical Sciences University, Tehran, Iran
Corresponding Author : Reza Rastmanesh
Department of Clinical Nutrition and Dietetics
Faculty of Nutrition Sciences and Food Technology
National Nutrition and Food Technology Research Institute
Shahid Beheshti University of Medical Sciences
Tehran- 4739, Iran
Tel: +9821-22357484 (ex 253)
Fax: +9821-22360660
E-mail: rezar@sbmu.ac.ir
Received August 27, 2013; Accepted October 07, 2013; Published October 09, 2013
Citation: Hejazi J, Rastmanesh R, Taleban FA, Molana SH, Ehtejab G (2013) A Pilot Clinical Trial of Radioprotective Effects of Curcumin Supplementation in Patients with Prostate Cancer. J Cancer Sci Ther 5:320-324. doi: 10.4172/1948-5956.1000222
Copyright: © 2013 Hejazi J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Cancer Science & Therapy

Abstract

Background: Patients with prostate cancer who accede to radiation therapy usually experience several side effects and these toxicities are sometimes dose limiting. Some previous in vitro and in vivo studies have proposed a radioprotective role for curcumin, the yellow pigment of turmeric.

Objectives: The purpose of this investigation was to assess the radioprotective effects of curcumin supplementation in patients with prostate cancer.

Methods: Forty prostate cancer patients undergoing external beam radiotherapy (EBRT) were randomly assigned to curcumin group, taking 3 g/d curcumin (6 × 500 mg capsules of BCM95 n=20), or placebo group (n=20). Quality of life was assessed by the Persian version of the European Organization for Research and Treatment of Cancer prostate cancer-specific quality of life questionnaire (QLQ-PR25).Analysis of covariance was used to compare radiotherapy related symptoms between groups following the intervention, adjusted for baseline symptoms.

Results: No differences in urinary symptoms, bowel symptoms, treatment related symptoms and sexual activity were observed between the curcumin and placebo groups before the intervention. The change in urinary symptoms across the 20-week period differed significantly between groups (p=0.011) and patients in the curcumin group experienced much milder urinary symptoms compared with the placebo group. No group differences were observed in any other domain of the QLQ-PR25.

Conclusions: Curcumin can confer radioprotective effect in patients with prostate cancer who undergo radiation therapy through reducing the severity of radiotherapy related urinary symptoms. However supplementation with 3 g/ day curcumin could not reduce the severity of bowel symptoms or other treatment related symptoms.

Keywords
Prostate cancer; Curcumin; Quality of life; Radioprotective
Introduction
Prostate cancer is the second most incident cancer among male population worldwide. It is the second leading cause of cancer death in American men [1]. There is no exact statistics on prostate cancer prevalence in Iran; however an estimation of 5 per 100,000 and 9 per 100,000 has been reported by two investigators [2,3]. A possible reason for this lower incidence comparing with many other countries is that there are no national programs for screening of prostate cancer in Iran.
Radiation therapy by itself or along with surgery and hormone therapy are the main treatments for prostate cancer [4]. However ionizing radiation can also have a harmful effect on healthy body tissues. Patients with prostate cancer who accede to radiation therapy usually experience some degrees of sexual dysfunction, gastrointestinal disorders and urinary tract problems [5]. These toxicities are known to be dose-limiting, [6] and because higher radiation doses for patients with clinically localized prostate cancer are now considered standard of care [7], finding ways to decrease symptoms burden is crucial.
Recently some in vitro and in vivo studies showed radiosensitizing and radioprotective effects by some phytochemicals [8]. One of these phytochemicals is curcumin. Curcumin is the yellow coloring agent in the spice, turmeric. Turmeric has been long used as a spice and food additive in Iranian cuisines. Curcumin has been reported to protect various study systems, in vitro and in vivo, against the deleterious effects induced by ionizing radiation and to enhance the effect of radiation [9-11]. Therefore, curcumin has the potential to be very useful during radiotherapy of prostate cancer.
The present pilot double blinded placebo controlled clinical trial, is designed to assess radioprotective effects of curcumin supplementation in patients with prostate cancer. To the best of our knowledge this is the first reported clinical trial testing curcumin supplement to test quality of life in patients with prostate cancer.
Materials and Methods
Between March 2011 and March 2013, all patients recently diagnosed with localized prostate cancer at the Department of Oncology at Besat Hospital were assessed for eligibility. Patients referred to local curative radiotherapy with external beam radiotherapy (EBRT), in combination with hormone ablation, were invited to participate in the study (ClinicaltiralsNCT01917890). Adenocarcinoma of the prostate must be histologically confirmed on biopsy. All patients were with a life expectancy greater than 5 years. No metastatic disease must be detected during physical examination, standard radiography, bone scan, and magnetic resonance spectroscopy (MRS). Additional inclusion criteria were no prior hormone therapy, radiotherapy or systemic treatment for prostate cancer and no other malignancy. The exclusion criteria were clinical stage T3 or T4, Gleason score ≥ 8, serum PSA ≥ 20 ng/mL, other prior surgery for prostate cancer, concurrent participation in another clinical trial which would require approval upon entry to this trial, gastrointestinal disorders such as inflammatory bowel disease, reflux and peptic ulcers and any adverse reaction to curcumin. Forty five of 78 eligible patients agreed to participate and 40 patients completed the study (Figure 1). All patients gave their written informed consent prior to participation. The study was approved by the ethical committee of National Nutrition and Food Technology Research Institute.
EBRT was given as daily fractions of 2 Gy to achieve a total dose of 74 Gy (5 times a week for about 8 weeks). Data were collected 1 week prior to radiotherapy onset, at the same time as randomization and intervention onset, and 3 months after radiotherapy and intervention completion.
Randomization
Patients were randomly assigned to either the curcumin group (CG, n=43) or placebo group (PG, n=42) (Figure 1). Randomization was performed by administrative personnel outside the research project in a double-blind fashion. Random assignment was based on a computer-generated randomization list obtained using blocks of size 4.
Intervention
Curcumin capsules (BCM95 (Biocurcumin)) and their placebos were obtained as a generous donation from Arjuna Natural Extracts Ltd. Kerela, India, in 500 mg capsule form. Each curcumin capsule contained 440 mg curcuminoids (347 mg curcumin, 84 mg desmethoxycurcumin, and 9 mg bisdesmethoxycurcumin) and essential oil of turmeric 38 mg and each placebo capsule contained 500 mg roasted rice flour.
Patients in each group took 3 grams of curcumin or placebo (as 6 × 500 mg capsules, 2 capsules with each meal) since 1 week before onset of radiotherapy until completion of their radiotherapy.
All patients were advised to avoid any changes in their usual dietary habits during intervention period.
Evaluation during study
A complete history [pathologic confirmation of malignancy, disease staging, prior therapy/surgery, and prior response(s)] and a physical examination, as well as blood tests (including a complete blood count and PSA) were done at baseline by a trained physician.
All patients were referred to Babak imaging center for MRS. MRI/ MRSI studies were performed on a 1.5 Tesla Sigma Horizon scanner (GE, Milwaukee, WI) using a combined pelvic phased array and endorectal coil (Medrad, Indianola, PA). MRSI data were obtained and processed using software developed at the University of California in San Francisco.
Patients were weighed in light clothing and without shoes using a scale (Seca, Hamburg, Germany) and their height, measured with a stadiometer (Holtain Ltd, Crymych, United Kingdom), was used to calculate Body Mass Index (BMI).
A validated semi-quantitative food frequency questionnaire (FFQ) [12] was used to evaluate dietary intake of patients. For the extraction of polyphenols intake from foods in FFQ, the phenol-Explorer database was used. Phenol-Explorer database contains data on the content of 502 polyphenols in 452 foods [13].
The European Organization for Research and Treatment of Cancer (EORTC) prostate cancer-specific quality of life questionnaire module (QLQ-PR25) was used to assess urinary, sexual, and bowel function [14]. The questionnaire was translated from English into Persian and then translated back from Persian into English by a researcher fluent in both languages. Reliability (r=0.85) and construct validity (Cronbach alpha >0.7) had been determined in our pilot study with 41 patients. The test-retest reliability was satisfactory (Pearson r=0.61 to 0.93 for individual items and 0.85 for total score). The research team, several university faculty members, and a physician reviewed the pilot questionnaire to establish face validity and trustworthiness. The questionnaire was revised appropriately based on their feedback. Items were combined into several scales (from 1 to 100) according to EORTC rules. For the global health and function scales, a high score signaled a better QoL; for the symptom scales, a high score was indicative of a poorer QoL.
All the above evaluations were done at baseline (1 week before radiotherapy onset) and 3 months after radiotherapy completion.
Statistical analyses
Statistical analyses were performed using SPSS 19.0 (SPSS, Chicago, IL). All analyses were conducted on an intention-to-treat basis. All p-values were two-tailed and the level of statistical significance was set at p < 0.05. Between-group differences at baseline were analyzed using the chi-square test and the independent t-test.
Analysis of covariance (ANCOVA) adjusting for baseline was used to evaluate the effect of the intervention on side effects using data from QLQ-PR25.
Results
The two randomized groups were well balanced with no significant differences in characteristics at baseline (Table 1). All the patients who completed the study (40 out of 45 patients), took all their supplements and because we used face to face interview for completion of questionnaires, there was no missing answer.
There was no significant difference between the 2 groups in terms of 4 subclasses of QLQ-PR25 (urinary symptoms, bowel symptoms, treatment-related symptoms and sexual functioning) at baseline (Table 2). The change in urinary symptoms across the 20-week period differed significantly between groups (p=0.011, Table 2). Following the intervention, participants in the curcumin group had significantly lower increase in urinary symptoms comparing with placebo group. No group differences were observed in any other domain of the QLQPR25.
Figure 2 shows the number of patients with worsening different urinary symptoms 3 month after radiotherapy. As it is shown, patients in curcumin group experienced much milder problems in terms of most of the urinary symptoms specially urinate frequency during the day and limitation of their daily activities. Only 2 of our participants were wearing an incontinence aid so this part of questionnaire was not considered in our analysis.
Discussion
To our knowledge this is the first randomized controlled trial investigating the radioprotective effect of curcumin in prostate cancer patients. The primary finding of this analysis was that 3 g/day curcumin supplement can reduce the severity of radiotherapy related urinary symptoms in patients with prostate cancer.
The3g dose of curcumin was chosen based on the results of an in vitro study which has shown that curcumin in the concentration of 2 μM can confer radiosensitizing activity on human prostate cancer cells and enhance apoptosis [15]. Also a clinical trial has shown that by taking 2 g of BCM95the concentration of 2 μM is achievable in plasma [16]. Moreover according to the previous studies, this dose is absolutely safe [17]. However this dose of curcumin did not appear to be effective at reducing the severity of bowel symptoms or other treatment related symptoms. In the case of sexual function, although participants in curcumin group had better condition compared with placebo group, this difference did not reach statistical significance. Hormone deprivation therapy of the patients can be a possible confounding factor which can mask the true effect of curcumin, however it was a part of patients’ treatment program and could not be omitted. The non dose-finding design of this clinical trial could be seen as a limitation because the real effective dose of curcumin for these symptoms cannot be discerned and higher doses may have better protective effects.
In a recent clinical trial supplementation with 6 g/d of curcumin reduced the severity of radiation dermatitis in breast cancer patients [18]. Also, several in vitro and in vivo studies which were reviewed by Goel et al. have indicated that curcumin has the potential to be used as a radioprotective agent [19].
The majority of the acute urinary dysfunction caused by EBRT relates to inflammation and mucosal loss at the bladder neck and within the prostate and prostatic urethra [5]. Curcumin is a well-known and strong anti-inflammatory and anti-oxidant agent. The mechanisms responsible for the protective effect of curcumin on urinary were not specifically examined in this investigation. However some mechanisms have been proposed for the radioprotective effect of curcumin. In an in vivo study it had been shown that curcumin confers its radioprotective effect through decreasing gene expression of inflammatory (IL-1, IL-6, IL-18, TNFα, and lymphotoxin-β) and fibrogenic cytokine (TGFβ) [20]. Also it has been reported that curcumin scavenges free radicals, increases antioxidant status, inhibits lipid peroxidation, and elevates glutathione S-transferases, glutathione peroxidase, superoxide dismutases, glutathione, and sulphydryl groups [21].
Another issue which makes curcumin supplementation during radiation therapy an interesting possibility is the fact that any exposure to radiation raises concern about the possibility of a second malignancy. A population based study of 17,845 prostate cancer patients compared secondary cancer incidence in patients treated with radical prostatectomy and radio therapy [22]. The results showed that the risk of rectal cancer, bladder cancer and lung cancer in patients treated with radiotherapy are significantly higher compared with those who underwent radical prostatectomy. Curcumin is a potent anticancer agent which suppresses all 3 stages of carcinogenesis: initiation, promotion, and progression [19] and can be a promising anti-cancer treatment. There is a common concern that using antioxidants during radiotherapy may reduce the efficacy of treatment by protecting tumor cells from radiation-induced cell death. Despite of controversies about the impacts of antioxidant supplementation during radiation therapy on its outcomes, some recent studies have reported promising effects [23,24]. In the present study MRI/MRS results and PSA levels of patients in CG and PG was not significantly differed, 3 months after intervention completion (0.12 ± 0.17 and 0.13 ± 0.06, respectively). Thus it seems that at least in short term, curcumin does not have any unfavorable effect on treatment outcomes. Several in vitro studies have also proposed a radiosensitizing activity for curcumin by inhibition of radiation-induced elevation of growth factors, cytokines, cyclins, nuclear factor-κB and tumor necrosis factor-α on tumor cells [21] and probably these mechanisms are blunting the radioprotective effects of curcumin in tumor cells. The study of molecular mechanisms of radioprotective effect of curcumin on normal tissues and its radiosensitization on tumor cells is on its way by our research team.
There are some limitations associated with this investigation including the small sample size and short duration of follow up. Larger clinical trials with different doses of curcumin are desirable to further confirm curcumin radioprotective effects in different organs. The questionnaire was pilot tested to establish construct validity, but the questionnaire cannot be declared reliable without test-retest analysis in other studies.
Conclusion
The present clinical trial has shown that curcumin can confer radioprotective effect in patients with prostate cancer who undergo radiation therapy through reducing the severity of radiotherapy related urinary symptoms which are of the most common side effects of radiation therapy [5]. However supplementation with 3 g/day curcumin could not reduce the severity of bowel symptoms or other treatment related symptoms. Further studies with larger sample sizes and higher doses of curcumin are required to further confirm radioprotective effects of curcumin on different organs.
Acknowledgements
This study was part of PhD dissertation by the first author and was supported by the research grants from National Nutrition and Food Technology Research Institute, Iran National Science Foundation, and research deputy of Shahid Beheshti University of Medical Sciences. We gratefully acknowledge Arjuna Natural Extracts Ltd for providing the curcumin capsules and placebos.
This study was funded by grants from National Nutrition and Food Technology Research Institute, Iran National Science Foundation, and research deputy of Shahid Beheshti University of Medical Sciences.
References
























Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Abnormal Pap Test
Disc Acute Lymphoblastic Leukemia
Disc Acute Megakaryocytic Leukemia
Disc Acute Myelomonocytic Leukemia
Disc Acute Myleoid Leukemia
Disc Adenocarcinoma pancreas
Disc Advances in Alternative Lung Cancer Treatment
Disc Advances in Breast Cancer Treatment
Disc Aleukemic Leukemia
Disc Alternative Treatments for Breast Cancer
Disc Anal Cancer Diagnosis
Disc Anti-Cancer Drug
Disc Apoptosis
Disc Bile Duct Cancer
Disc Biliary Cancer
Disc Bladder Cancer Diagnosis
Disc Blood Cancer Diagnosis
Disc Bone Cancer Stages
Disc Bone Marrow Cancer Survival
Disc Brain Cancer Diagnosis
Disc Brain Tumor Treatment
Disc Breast Cancer Biology
Disc Breast Cancer Cure
Disc Breast Cancer Diagnosis
Disc Breast Cancer Grading
Disc Breast Cancer Prevention
Disc Breast Cancer Radiotherapy
Disc Breast Cancer Research
Disc Breast Cancer Surgery
Disc Breast Cancer Therapeutic & Market Analysis
Disc Breast Screening
Disc Cancer Diagnosis
Disc Cancer Science
Disc Cancer Therapies
Disc Cancer initiation and progression
Disc Cancer therapy
Disc Carcinogenesis
Disc Carcinoid Tumours
Disc Cellular Oncology
Disc Cervical Biopsy
Disc Cervical Cancer Diagnosis
Disc Cervical Cancer Prevention
Disc Cervical Cancer Treatment
Disc Cervical Intra-epithelial Neoplasia (CIN)
Disc Cervical Screening
Disc Cervix-Cancer
Disc Chemo Resistance
Disc Chronic Lymphocytic Leukemia
Disc Chronic Myleloid Leukemia
Disc Clinical Oncology
Disc Colon Cancer Diagnosis
Disc Colon Cancer Surgery
Disc Colorectal Cancer
Disc Colposcopy
Disc Comparative Oncology
Disc Cone Biopsy
Disc DNA damage
Disc Dental Oncology
Disc Dermatologic Surgery
Disc Ductal adenocarcinoma
Disc Duodenal Cancer
Disc Electro Chemotherapy
Disc Esophageal Cancer
Disc Esophageal Cancer Diagnosis
Disc Feline Leukemia Complex
Disc Fibrocystic Breast
Disc Gall Bladder Cancer
Disc Gastro Intestinal Cancer Treatment
Disc Gastro Intestinal Stromal Tumours
Disc Gastroesophageal (GE) Junction Cancer
Disc Gastrointestinal Carcinoid Tumours
Disc Genital Warts
Disc Genitourinary Oncology
Disc Germ cell tumours
Disc Gynecological Cancers
Disc HPV Vaccination
Disc Hairy Cell Leukemia
Disc Hereditary Breast Cancer
Disc Human Immunodeficiency Virus (HIV)
Disc Human Papillomavirus (HPV)
Disc Inflammatory Breast Cancer
Disc Interventional Oncology
Disc Invasive Ductal Carcinoma
Disc Jaundice
Disc Kidney Cancer Diagnosis
Disc Kidney Cancer Prognosis
Disc Kidney Cancer Surgery
Disc Leukemia
Disc Leukemia Diagnosis
Disc Leukemia Drugs
Disc Leukemia Surgery
Disc Liver Cancer Diagnosis
Disc Lung Cancer Diagnosis
Disc Lung Cancer Surgery
Disc Lung Tumor
Disc Lungs Cancer Cure
Disc Lymph Node Cancer
Disc Lymphoma Cancer
Disc Lymphoma Diagnosis
Disc Lymphoma Surgery
Disc Lymphoma Symptoms
Disc Lymphomatous polyposis
Disc Lymphosarcoma
Disc Making Strides in Breast Cancer
Disc Mast Cell Leukemia
Disc Mastectomy
Disc Mesothelioma Diagnosis
Disc Metastatic Breast Cancer
Disc Molecular Oncology
Disc Mouth Cancer Diagnosis
Disc Musculoskeletal Oncology
Disc Mutagenesis
Disc Neurofibromatosis Type 1
Disc Oesophageal Cancer
Disc Oesophageal Cancer Surgery
Disc Oncology Analytics
Disc Oncology Emergency
Disc Oncology Esthetics
Disc Oncology Nutrition
Disc Oseophagus Cancer
Disc Ovarian Cancer Diagnosis
Disc Ovarian Cancer and Prognosis
Disc Pancreatic Cancer
Disc Pancreatic Cancer Diagnosis
Disc Pancreatic Cancer Surgery
Disc Pancreatic Islet Cell Cancer
Disc Papanicolaou Screening
Disc Pediatric Leukemia
Disc Photo carcinogenesis
Disc Plasma Cell Leukemia
Disc Prostate Cancer Diagnosis
Disc Prostate Cancer Surgery
Disc Radiation Therapy
Disc Radio Oncology
Disc Radiotherapy
Disc Radiotherapy for Breast Cancer
Disc Rectal Cancer Diagnosis
Disc Sarcoma Cancer
Disc Sexually Transmitted Disease (STD)
Disc Skin Cancer Diagnosis
Disc Skin Cancer Surgery
Disc Small Bowel Cancer
Disc Small Intestine Cancer
Disc Smoking in Breast Cancer
Disc Spleen Cancer
Disc Squamous Cell Cancer (SCC)
Disc Squamous Cell Carcinoma
Disc Stomach Cancer
Disc Stomach Cancer Surgery
Disc Terminal Breast Cancer
Disc Testicular Cancer Diagnosis
Disc Thoracic Oncology
Disc Throat Cancer Surgery
Disc Thyroid Cancer Diagnosis
Disc Thyroid Cancer Surgery
Disc Tumorigenesis
Disc Uterine Cancer Diagnosis
Disc Vaginal Oncology
Disc Venereal Disease
Disc Veterinary Oncology
 
Recommended Journals
Disc Gastrointestinal Cancer Journal
Disc Colorectal Cancer Journal
Disc Cervical Cancer Journal
Disc Breast Cancer Journal
Disc Cancer Surgery Journal
Disc Cancer Diagnosis Journal
Disc Leukemia Journal
Disc Integrative Oncology Journal
Disc Carcinogenesis & Mutagenesis Journal
Disc Chemotherapy Journal
  View More»
 
Recommended Conferences
Disc 11th Oncologists Meeting
July 11-13, 2016 Kuala Lumpur, Malaysia
Disc 10th Global Nursing & Healthcare Conference
August 18-20, 2016 São Paulo, Brazil
Disc 2nd World Congress on Breast Cancer
September 19-21, 2016 Phoenix, Arizona,USA
Disc Oncology Nursing Congress
September 19-21, 2016 Las Vegas, USA
Disc 12th Cancer Therapy Conference
September 26-28, 2016 London, UK
Disc 3rd World Congress on Women’s Health and Breast Cancer
October 03-05, 2016 London, UK
Disc 15th Euro Nursing & Medicare Summit
October 17-19, 2016 Rome, Italy
Disc 13th Cancer Therapy Summit
October 17-19, 2016 Dubai, UAE
Disc 6th Cancer Therapy Congress
December 01-03, 2016 Baltimore, USA
Disc 10th Nursing and Healthcare
December 05-07, 2016 Dallas, USA
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11506
  [From(publication date):
October-2013 - Jun 27, 2016]
  Breakdown by view type
  HTML page views : 7758
  PDF downloads :3748
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version